Cargando…

Cost-utility analysis of a universal pneumococcal vaccination programme for older adults in Norway

The aim of this study was to establish whether a universal pneumococcal vaccination for older adults in Norway is likely to be cost-effective from the perspective of the health care provider. A decision tree model developed by the Public Health Agency of Sweden was adopted to the Norwegian setting....

Descripción completa

Detalles Bibliográficos
Autores principales: Nymark, Liv Solvår, Dag Berild, Jacob, Lyngstad, Trude Marie, Askeland Winje, Brita, Frimann Vestrheim, Didrik, Aaberge, Ingeborg, Juvet, Lene Kristine, Wolff, Ellen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746426/
https://www.ncbi.nlm.nih.gov/pubmed/35917277
http://dx.doi.org/10.1080/21645515.2022.2101333
_version_ 1784849356793315328
author Nymark, Liv Solvår
Dag Berild, Jacob
Lyngstad, Trude Marie
Askeland Winje, Brita
Frimann Vestrheim, Didrik
Aaberge, Ingeborg
Juvet, Lene Kristine
Wolff, Ellen
author_facet Nymark, Liv Solvår
Dag Berild, Jacob
Lyngstad, Trude Marie
Askeland Winje, Brita
Frimann Vestrheim, Didrik
Aaberge, Ingeborg
Juvet, Lene Kristine
Wolff, Ellen
author_sort Nymark, Liv Solvår
collection PubMed
description The aim of this study was to establish whether a universal pneumococcal vaccination for older adults in Norway is likely to be cost-effective from the perspective of the health care provider. A decision tree model developed by the Public Health Agency of Sweden was adopted to the Norwegian setting. Two cohorts, consisting of 65-year-olds and 75-year-olds grouped into vaccinated and unvaccinated, were followed over a 5-year time horizon. In the base case, the 23-valent polysaccharide vaccine (PPV23) was used while the 13-valent pneumococcal conjugate vaccine (PCV13) was included in scenario analyses only. The costs and health benefits (measured in quality adjusted life years (QALY) gained) were compared in the two cohorts between the vaccinated and unvaccinated groups. The impact of indirect effects of the vaccine, such as herd immunity and serotype replacement, were not investigated. The relative importance of change in price was assessed by performing one-way sensitivity analyses. Under base-case assumptions, the programme for the 75-year-old cohort is expected to be cost-effective from the health care perspective at the current pharmacy purchasing price and at 75% vaccination coverage as it falls below the lower end of the cost-effectiveness threshold range (NOK 9467/EUR 964). In comparison, for the 65-year-old cohort the cost per QALY gained is approximately NOK 780 206 (EUR 79 451) under the base-case assumptions which falls within the acceptable ranges in a Norwegian context for both the 65- and 75-year-old cohorts. There is no exact cost-effectiveness threshold in Norway. However, introducing a vaccination programme against pneumococcal disease for 65-year-olds and 75-year-olds in Norway is likely to fall within the acceptable cost-effectiveness threshold range.
format Online
Article
Text
id pubmed-9746426
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-97464262022-12-14 Cost-utility analysis of a universal pneumococcal vaccination programme for older adults in Norway Nymark, Liv Solvår Dag Berild, Jacob Lyngstad, Trude Marie Askeland Winje, Brita Frimann Vestrheim, Didrik Aaberge, Ingeborg Juvet, Lene Kristine Wolff, Ellen Hum Vaccin Immunother Pneumococcal – Research Article The aim of this study was to establish whether a universal pneumococcal vaccination for older adults in Norway is likely to be cost-effective from the perspective of the health care provider. A decision tree model developed by the Public Health Agency of Sweden was adopted to the Norwegian setting. Two cohorts, consisting of 65-year-olds and 75-year-olds grouped into vaccinated and unvaccinated, were followed over a 5-year time horizon. In the base case, the 23-valent polysaccharide vaccine (PPV23) was used while the 13-valent pneumococcal conjugate vaccine (PCV13) was included in scenario analyses only. The costs and health benefits (measured in quality adjusted life years (QALY) gained) were compared in the two cohorts between the vaccinated and unvaccinated groups. The impact of indirect effects of the vaccine, such as herd immunity and serotype replacement, were not investigated. The relative importance of change in price was assessed by performing one-way sensitivity analyses. Under base-case assumptions, the programme for the 75-year-old cohort is expected to be cost-effective from the health care perspective at the current pharmacy purchasing price and at 75% vaccination coverage as it falls below the lower end of the cost-effectiveness threshold range (NOK 9467/EUR 964). In comparison, for the 65-year-old cohort the cost per QALY gained is approximately NOK 780 206 (EUR 79 451) under the base-case assumptions which falls within the acceptable ranges in a Norwegian context for both the 65- and 75-year-old cohorts. There is no exact cost-effectiveness threshold in Norway. However, introducing a vaccination programme against pneumococcal disease for 65-year-olds and 75-year-olds in Norway is likely to fall within the acceptable cost-effectiveness threshold range. Taylor & Francis 2022-08-02 /pmc/articles/PMC9746426/ /pubmed/35917277 http://dx.doi.org/10.1080/21645515.2022.2101333 Text en © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Pneumococcal – Research Article
Nymark, Liv Solvår
Dag Berild, Jacob
Lyngstad, Trude Marie
Askeland Winje, Brita
Frimann Vestrheim, Didrik
Aaberge, Ingeborg
Juvet, Lene Kristine
Wolff, Ellen
Cost-utility analysis of a universal pneumococcal vaccination programme for older adults in Norway
title Cost-utility analysis of a universal pneumococcal vaccination programme for older adults in Norway
title_full Cost-utility analysis of a universal pneumococcal vaccination programme for older adults in Norway
title_fullStr Cost-utility analysis of a universal pneumococcal vaccination programme for older adults in Norway
title_full_unstemmed Cost-utility analysis of a universal pneumococcal vaccination programme for older adults in Norway
title_short Cost-utility analysis of a universal pneumococcal vaccination programme for older adults in Norway
title_sort cost-utility analysis of a universal pneumococcal vaccination programme for older adults in norway
topic Pneumococcal – Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746426/
https://www.ncbi.nlm.nih.gov/pubmed/35917277
http://dx.doi.org/10.1080/21645515.2022.2101333
work_keys_str_mv AT nymarklivsolvar costutilityanalysisofauniversalpneumococcalvaccinationprogrammeforolderadultsinnorway
AT dagberildjacob costutilityanalysisofauniversalpneumococcalvaccinationprogrammeforolderadultsinnorway
AT lyngstadtrudemarie costutilityanalysisofauniversalpneumococcalvaccinationprogrammeforolderadultsinnorway
AT askelandwinjebrita costutilityanalysisofauniversalpneumococcalvaccinationprogrammeforolderadultsinnorway
AT frimannvestrheimdidrik costutilityanalysisofauniversalpneumococcalvaccinationprogrammeforolderadultsinnorway
AT aabergeingeborg costutilityanalysisofauniversalpneumococcalvaccinationprogrammeforolderadultsinnorway
AT juvetlenekristine costutilityanalysisofauniversalpneumococcalvaccinationprogrammeforolderadultsinnorway
AT wolffellen costutilityanalysisofauniversalpneumococcalvaccinationprogrammeforolderadultsinnorway